





**14<sup>th</sup> October 2022**

Immunisations are the most cost effective health intervention available, but concerns are mounting about the return of previously rare but serious and potentially fatal infectious diseases, due to decreased immunisation coverage in Ireland amongst babies and children.

### **National Overview - Primary Childhood Immunisation Programme (PCI)**

Data extracted from

[Immunisation uptake in Ireland at 12 and 24 months - data up to Quarter 1, 2022](#)




## CHO 2 Overview

### PCI – 6 in1 Vaccine (Q1 2022)

The following map shows uptake of 6 in 1 vaccine at 12 months was 91.7% in Q1 2022 in CHO 2; a decrease of 0.82% compared to Q4 2021. In comparison, national uptake was 87.9% in Q1 2022.

Among the LHOs of CHO 2 uptake of the 6 in 1 vaccine at 12 months ranged from 90.3% in Mayo to an excellent uptake of 96% in Roscommon, which exceeded the national target.




The HSE, DoH CMO and NIAC are concerned that Ireland may experience outbreaks of Polio if we do not increase our uptake of polio containing vaccines. The last reported case of Polio in Ireland was in 1984.

### PCI – MMR Vaccine

This map shows the uptake of MMR1 at 24 months was 92.6% in Q1 2022 in CHO 2; a decrease of 2.1% compared to Q4 2021. In comparison, national uptake was 89.7% in Q1 2022.

Among the LHOs of CHO 2 uptake of MMR1 at 24 months ranged from 92.3% in Mayo to 93.4% in Roscommon. The uptakes across the LHOs in your area are to be commended, and with further improvements can meet the national target of 95%.




## Schools – Junior Infants primary schools

Data extracted from SIS by NIO on 09/10/2022.

The following graph for CHO 2 shows while Roscommon and Mayo are very close to achieving the 95% target for the 4 in 1 vaccine, the overall data for the 2021/2022 academic year is reported at 85%.


This graph shows the uptake for the MMR in CHO2 is at 85.5% which falls significantly short of the national target. An investigation into where improvements could be made is recommended.



## Schools – First Year second level schools

The overall uptake in CHO 2 for the 2021/2022 academic years shows while HPV 1 uptake is reported at 80.69% and HPV 2 is reported at 77.20%. It is recommended that investigation is carried out into what improvements could be made to achieve the 85% national target.

The figures for MenACWY uptake at 83.58% and Tdap at 84.5% also show investigation is required into understanding where improvements could be achieved to achieve the 95% target.




## CHO 2 - Galway

### Primary Childhood Immunisation Programme (PCI)


Data extracted from

#### Immunisation uptake in Ireland at 12 and 24 months - data up to Quarter 1, 2022

The uptake of the 6 in 1 vaccine at 12 months was 91.3% in Q1 2022 in Galway; a decrease of 0.07% compared to Q4 2021. In comparison, uptake was 91.7% in CHO2 and 87.9% in Ireland in Q1 2022.



The uptake of the MMR1 vaccine at 24 months was 92.5% in Q1 2022 in Galway; a decrease of 2.65% compared to Q4 2021. In comparison, uptake was 92.6% in CHO2 and 89.7% in Ireland in Q1 2022.



While it is welcome that each vaccine has achieved over 90%, investigation is required to understand why there were declines and seek improvements.


We would encourage you to continue to work to achieve 95% uptake in the next reporting quarter.

The HPSC report also highlights uptakes surpassing 90% across the 12 month schedule in Galway. While there are notable uptakes reported with 6 in 1 vaccine at 93.7% and Rota2 at 94.7%, there are declines in uptake across the entire 24 month schedule. These declines should be investigated to see if trends are emerging and establish what improvements can be made.


### **School Immunisation Programme (SIP) 2021/2022**

Data extracted from SIS by NIO on 09/10/2022

Primary school programme



Second level school programme



The reported numbers uptake in Galway of HPV 1 at 79.09% and HPV 2 at 76.77% also merit investigation as to where improvements can be achieved to reach the national target of 85%. The reported MenACWY uptake at 81.271% is an area of concern, falling short of the national target of 95%.

**A reminder that the HSE KPI for vaccines is set at 95% (and for HPV is 85%)**


## CHO 2 – Mayo

### Primary Childhood Immunisation Programme (PCI)


Data extracted from

[Immunisation uptake in Ireland at 12 and 24 months - data up to Quarter 1, 2022 \[Excel\]](#)

The following graph shows uptake of the 6 in 1 vaccine at 12 months was 90.3% in Q1 2022 in Mayo; a decrease of 2.48% compared to Q4 2021. In comparison, uptake was 91.7% in CHO2 and 87.9% in Ireland in Q1 2022.



This graph shows the uptake of MMR1 at 24 months was 92.3% in Q1 2022 in Mayo; a decrease of 1.74% compared to Q4 2021. In comparison, uptake was 92.6% in CHO2 and 89.7% in Ireland in Q1 2022.




We acknowledge these strong performances and would also encourage you to investigate these declines and include recommendations to improve uptake in the next reporting quarter.

The HPSC report also highlights a strong performance albeit with declines in uptake across the 12 month schedule in Mayo. Notably MenB2 at 94.5% and Rota2 at 94.8%, both just short of target. Similarly there have been declines across the 24 month schedule, while yet again approaching the national target in a number of vaccines. Efforts should be made in to investigating not just the declines, but in to how uptake can be improved to achieve 95%.


### **School Immunisation Programme (SIP) 2021/2022**

Data extracted from SIS by NIO on 09/10/2022

Primary school programme



Second level school programme



Reported data in Mayo shows impressive HPV 1 uptake at 83.32% and HPV 2 at 76.9%. While it's important to acknowledge HPV 1 is approaching the 85% target, the decline for HPV 2 is so significant it merits investigation and recommendations for improvement. MenACWY at 86.11 also falls short of the national target of 95%.

**A reminder that the HSE KPI for vaccines is set at 95% (and for HPV is 85%)**


## CHO 2 – Roscommon

### Primary Childhood Immunisation Programme (PCI)

Data extracted from

[Immunisation uptake in Ireland at 12 and 24 months - data up to Quarter 1, 2022 \[Excel\]](#)


The following graph represents uptake of the 6 in 1 vaccine for Roscommon at 12 and 24 months.



It shows uptake of the 6 in 1 vaccine at 12 months exceeded the national target with 96.0% in Q1 2022 in Roscommon; a decrease of 0.7% compared to Q4 2021. We must congratulate Roscommon for their efforts in this area.

In comparison, uptake was 91.7% in CHO2 and 87.9% in Ireland in Q1 2022.

The following graph represent uptake of the MMR vaccine in Roscommon at 24 months was 93.4% in Q1 2022 a decrease of 0.93% compared to Q4 2021. While declines should be monitored for trends and improvements, the overall uptake is to be commended. In comparison, uptake was 92.6% in CHO2 and 89.7% in Ireland in Q1 2022.




The HPSC report highlights improvements in uptake across the 12 month vaccine schedule, with every vaccine notably exceeding the national target. A special mention must be given to the 99% achieved with Rota2, exceptional even in a high performing uptake report.

The data for the 24 month schedule reveals a contrast of declines and improvements across vaccines with yet another 99% achieved this time with MenB. Overall the 24 month schedule performs strongly in Roscommon, however some attention must be given to MenC2 which falls short of the national target at 86.4%.


### **School Immunisation Programme (SIP) 2021/2022**

Data extracted from SIS by NIO on 09/10/2022

Primary school programme



Second level school programme



Reported data for Roscommon in the academic year 2021/22 shows HPV1 uptake at 84.91% and HPV 2 uptake at 79.92%. While uptake for HPV 1 is commendable for approaching the national target of 85%, there is a significant drop off in HPV 2.

MenACWY uptake in Roscommon is recorded at 89.26%.

**A reminder that the HSE KPI for vaccines is set at 95% (and for HPV is 85%)**